Cargando…

CD4 derived double negative T cells prevent the development and progression of nonalcoholic steatohepatitis

Hepatic inflammation is the driving force for the development and progression of NASH. Treatment targeting inflammation is believed to be beneficial. In this study, adoptive transfer of CD4(+) T cells converted double negative T cells (cDNT) protects mice from diet-induced liver fat accumulation, lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Guangyong, Zhao, Xinyan, Li, Mingyang, Zhang, Chunpan, Jin, Hua, Li, Changying, Liu, Liwei, Wang, Yaning, Shi, Wen, Tian, Dan, Xu, Hufeng, Tian, Yue, Wu, Yongle, Liu, Kai, Zhang, Zhongtao, Zhang, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844244/
https://www.ncbi.nlm.nih.gov/pubmed/33510172
http://dx.doi.org/10.1038/s41467-021-20941-x
Descripción
Sumario:Hepatic inflammation is the driving force for the development and progression of NASH. Treatment targeting inflammation is believed to be beneficial. In this study, adoptive transfer of CD4(+) T cells converted double negative T cells (cDNT) protects mice from diet-induced liver fat accumulation, lobular inflammation and focal necrosis. cDNT selectively suppress liver-infiltrating Th17 cells and proinflammatory M1 macrophages. IL-10 secreted by M2 macrophages decreases the survival and function of cDNT to protect M2 macrophages from cDNT-mediated lysis. NKG2A, a cell inhibitory molecule, contributes to IL-10 induced apoptosis and dampened suppressive function of cDNT. In conclusion, ex vivo-generated cDNT exert potent protection in diet induced obesity, type 2 diabetes and NASH. The improvement of outcome is due to the inhibition on liver inflammatory cells. This study supports the concept and the feasibility of potentially utilizing this autologous immune cell-based therapy for the treatment of NASH.